Key facts
- BigHat Biosciences’s last known valuation is $332.0M (Apr 2025).
- It has raised $148.3M across 3 recorded rounds; the latest was Later Stage VC ($124.1M) in Jun 2022.
- Notable investors include Andreessen Horowitz, Gaingels, 8VC, Samsung Venture Investment, Kevin Moore — 25 tracked in total.
- BigHat Biosciences has filed 4 Form Ds with the SEC since 2019, most recently Apr 2025 ($124.1M sold to 40 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for BigHat Biosciences
Funding rounds
3 roundsAbout BigHat Biosciences
Developer of an experimental antibody platform designed to empower biological antibodies and other therapeutic proteins. The company's platform is agile, multi-objective, and data-driven and integrates a wet laboratory with artificial intelligence and machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2019
- Employees
- 99
- Website
- bighatbio.com/
- Ownership
- Privately Held (backing)
BigHat Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BigHat Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BigHat Biosciences in its N-PORT filings yet. We sweep new filings monthly.